PMID- 25549697
OWN - NLM
STAT- MEDLINE
DCOM- 20160106
LR  - 20181202
IS  - 1502-4725 (Electronic)
IS  - 0803-9488 (Linking)
VI  - 69
IP  - 6
DP  - 2015 Aug
TI  - Effects of paliperidone extended release on functioning level and symptoms of 
      patients with recent onset schizophrenia: An open-label, single-arm, 
      flexible-dose, 12-months follow-up study.
PG  - 426-32
LID - 10.3109/08039488.2014.996252 [doi]
AB  - BACKGROUND: Response to antipsychotic treatment is better in the early stages of 
      schizophrenia. AIMS: The primary objective of this non-randomized, single-arm, 
      multicenter clinical trial was to explore the response to treatment and safety of 
      a flexible dose of paliperidone (mean = 6.42 mg/day) in patients with recent 
      onset schizophrenia (< 3 years after the first episode/hospitalization). METHODS: 
      Severity of clinical symptoms was evaluated by the Positive and Negative Syndrome 
      Scale (PANSS), functioning was assessed using the Global Assessment of 
      Functioning (GAF) scale and the Personal and Social Performance Scale (PSP). 
      RESULTS: In a total of 85 patients enrolled, 80 patients were eligible. Total PSP 
      score at baseline (50.2 +/- 11.6) increased at all visits. Total PSP score was 65.4 
      +/- 12.1 at month 12 (P < 0.001). GAF scores were significantly higher at all 
      visits compared with baseline (P = 0.001). It was 62.4 +/- 12.5 with an increase of 
      42.9% at month 12 (P < 0.001). PANSS Positive and Negative subscales and General 
      psychopathology subscale scores showed significant reductions beginning with 
      month 3 and were 11.9 +/- 3.8 (29.3%; P < 0.001), 13.7 +/- 5.6 (27.3% P < 0.001) and 
      27.8 +/- 7.1 (23.2%; P < 0.001) at month 12, respectively. Twelve patients (14.3%) 
      had a serious adverse event. The most common adverse events were insomnia 
      (17.9%), nausea (8.3%), akathisia (4.8%), anxiety (4.8%) and depression (4.8%). 
      Body weight values at the end of the study were significantly higher compared 
      with baseline. CONCLUSION: The present study demonstrates that flexible dose of 
      paliperidone resulted in a significant improvement in functioning and reduction 
      in symptoms in patients with recent onset schizophrenia.
FAU - Ucok, Alp
AU  - Ucok A
AD  - Alp Ucok, M.D., Professor of Psychiatry, Istanbul University, Istanbul Faculty of 
      Medicine , Istanbul , Turkey.
FAU - Saka, Meram Can
AU  - Saka MC
FAU - Bilici, Mustafa
AU  - Bilici M
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20141231
PL  - England
TA  - Nord J Psychiatry
JT  - Nordic journal of psychiatry
JID - 100927567
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Delayed-Action Preparations)
RN  - R8P8USM8FR (Paliperidone Palmitate)
SB  - IM
MH  - Adult
MH  - Antipsychotic Agents/adverse effects/*therapeutic use
MH  - Delayed-Action Preparations
MH  - Dose-Response Relationship, Drug
MH  - Drug Substitution
MH  - Female
MH  - Humans
MH  - Intention to Treat Analysis
MH  - Male
MH  - Paliperidone Palmitate/adverse effects/*therapeutic use
MH  - Psychiatric Status Rating Scales
MH  - Schizophrenia/diagnosis/*drug therapy
MH  - *Schizophrenic Psychology
OTO - NOTNLM
OT  - Functioning
OT  - Paliperidone ER
OT  - Schizophrenia
EDAT- 2015/01/01 06:00
MHDA- 2016/01/07 06:00
CRDT- 2015/01/01 06:00
PHST- 2015/01/01 06:00 [entrez]
PHST- 2015/01/01 06:00 [pubmed]
PHST- 2016/01/07 06:00 [medline]
AID - 10.3109/08039488.2014.996252 [doi]
PST - ppublish
SO  - Nord J Psychiatry. 2015 Aug;69(6):426-32. doi: 10.3109/08039488.2014.996252. Epub 
      2014 Dec 31.